Sign In
Buy OMER
$10.16
-0.1000 (-0.97%)
At Close: Jun 03, 2026
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
04:02pm, Tuesday, 31'st Mar 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, whi
Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average – Here’s Why
02:10am, Tuesday, 31'st Mar 2026
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.71 and traded as high as $
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
08:45am, Thursday, 26'th Mar 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
03:23am, Saturday, 21'st Mar 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantatio
Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of “Moderate Buy” by Brokerages
03:12am, Wednesday, 18'th Mar 2026
Omeros Corporation (NASDAQ: OMER - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are covering the stock, MarketBeat.com reports. One equities re
Reviewing Senestech (NASDAQ:SNES) & Omeros (NASDAQ:OMER)
02:37am, Monday, 09'th Mar 2026
Senestech (NASDAQ: SNES - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
08:45am, Tuesday, 17'th Feb 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ca
Omeros Announces First Commercial Sales of YARTEMLEA®
09:00am, Tuesday, 27'th Jan 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with ord
David Borges Sells 30,000 Shares of Omeros (NASDAQ:OMER) Stock
04:48am, Friday, 16'th Jan 2026
Omeros Corporation (NASDAQ: OMER - Get Free Report) CAO David Borges sold 30,000 shares of the company's stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of
Omeros (NASDAQ:OMER) Trading Down 5.8% After Insider Selling
01:18am, Friday, 16'th Jan 2026
Omeros Corporation (NASDAQ: OMER - Get Free Report) shares dropped 5.8% on Thursday following insider selling activity. The stock traded as low as $12.42 and last traded at $12.3160. Approximately 244
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus
03:06am, Friday, 09'th Jan 2026
Omeros (NASDAQ: OMER) outlined its U.S. launch plans for Yarcomlia (narsoplimab) and discussed clinical data, reimbursement preparations, and supply expectations following the drug's FDA approval on D
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
09:07pm, Wednesday, 07'th Jan 2026
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript
Omeros prices transplant complication drug at $36,000 per dose
06:50pm, Wednesday, 07'th Jan 2026
Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a c
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:23am, Friday, 02'nd Jan 2026
Omeros Corporation (NASDAQ: OMER - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings repo
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA
12:02pm, Monday, 29'th Dec 2025
OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.
